ING Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

ING Group’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-40,000	Closed	-$2.35M	–	639
2023 Q4	$2.35M	Buy	+40,000	New	+$2.25M	0.02%	389

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ING Group's MRTX Position: Q1 2024 in Review

ING Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 40,000 shares — an estimated $2.35M sold.

ING Group first reported a position in MRTX in Q4 2023 and held it in 1 quarter. The position peaked at $2.35M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

ING Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
ING Group sold 40,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.35M.
ING Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
ING Group's Mirati Therapeutics, Inc. Common Stock position peaked at $2.35M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on ING Group's 13F filing for Q1 2024, filed 10 May 2024.